**1. Introduction**

The success of coronary artery bypass grafting (CABG) surgery mainly depends on the pa‐ tency of graft vessels. The predominant mechanism of early graft failure after coronary sur‐ gery is associated with antiplatelet treatment using drungs such as acetylsalicylic acid (ASA). Prevention using oral ASA in the early postoperative phase in patients with vascular disease is associated with a 25% to 44% reduction in adverse cardiovascular events (1; 2). Daily ASA doses ranging between 75-1200mg can similarly reduce fatal and nonfatal events (2; 3), although studies directly comparing lower and higher doses with regard to clinical outcomes in the CABG setting have been lacking [4].
